Skip to search formSkip to main contentSkip to account menu

STA 9090

Known as: Hsp90 Inhibitor STA-9090, STA-9090, STA9090 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Triazoles

Narrower (1)

ganetespib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma
Uveal melanoma (UM) is a rare form of melanoma without effective therapy. The biology of UM relies on several heat-shock protein… 
2015
2015
A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma
SummaryBackground Ganetespib (STA-9090) is an Hsp90 inhibitor that downregulates VEGFR, c-MET, HER2, IGF-IR, EGFR, and other… 
Review
2015
Review
2015
Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations.
Review
2013
Review
2013
Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.
Highly Cited
2013
Highly Cited
2013
A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies
BackgroundThis phase I study investigated the maximum tolerated dose (MTD), safety, pharmacokinetics and antitumor activity of… 
Highly Cited
2011
Highly Cited
2011
Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy
Targeted inhibition of the molecular chaperone Hsp90 results in the simultaneous blockade of multiple oncogenic signaling… 
Highly Cited
2011
Highly Cited
2011
An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).
7500 Background: Ganetespib is a potent, next-generation Hsp90 inhibitor that is structurally unrelated to the first-generation… 
2011
2011
An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST.
10011 Background: Ganetespib, a potent, synthetic small-molecule inhibitor of Hsp90, has shown an improved safety profile… 
2011
2011
Phase I Evaluation of STA-1474, a Prodrug of the Novel HSP90 Inhibitor Ganetespib, in Dogs with Spontaneous Cancer
Background The novel water soluble compound STA-1474 is metabolized to ganetespib (formerly STA-9090), a potent HSP90 inhibitor… 
Highly Cited
2009
Highly Cited
2009
The novel HSP90 inhibitor STA‐1474 exhibits biologic activity against osteosarcoma cell lines
Osteosarcoma (OSA), the most common malignant bone tumor in dogs and children, exhibits a similar clinical presentation and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)